Nunes C, Ladeira S
Health Region of the Algarve, Portimão, Portugal.
J Investig Allergol Clin Immunol. 2000 Jan-Feb;10(1):20-3.
The aim of this double-blind study was to evaluate the effectiveness of cetirizine and loratadine versus placebo in patients with allergic rhinitis. The study included a total of 90 patients suffering from moderate to severe allergic rhinitis as determined by a symptom score, with hypersensitivity to house mites and with high IgE. The study lasted 7 weeks, including 1 for pretreatment, 4 for treatment and 2 posttreatment (washout). During the study, each patient received either one tablet of placebo, 10 mg of cetirizine or 10 mg of loratadine daily. The evaluation was carried out by rhinomanometry to analyze the symptoms on days 1, 15, 29 and 43. The nasal cytology was analyzed on days 1 and 29. For statistical analysis we used the Mantel-Haenszel method and chi-square test. We found that antihistamines showed good effectiveness in improving the symptomatology in patients with allergic rhinitis. The improvement by rhinomanometry and by symptom score versus placebo was good. It was concluded that both antihistamines were significantly superior to placebo and that cetirizine performed better in comparison to loratadine versus placebo, although not as statistically significant.
这项双盲研究的目的是评估西替利嗪和氯雷他定对比安慰剂治疗过敏性鼻炎患者的有效性。该研究共纳入90例中度至重度过敏性鼻炎患者，根据症状评分确定，对屋尘螨过敏且IgE水平高。研究持续7周，包括1周预处理期、4周治疗期和2周治疗后（洗脱期）。在研究期间，每位患者每天服用一片安慰剂、10毫克西替利嗪或10毫克氯雷他定。在第1、15、29和43天通过鼻阻力测量法进行评估以分析症状。在第1天和第29天分析鼻细胞学。对于统计分析，我们使用Mantel-Haenszel方法和卡方检验。我们发现抗组胺药在改善过敏性鼻炎患者的症状方面显示出良好的有效性。与安慰剂相比，通过鼻阻力测量法和症状评分的改善效果良好。得出的结论是，两种抗组胺药均明显优于安慰剂，并且与安慰剂相比，西替利嗪比氯雷他定表现更好，尽管在统计学上不显著。
